RxDoctor Payments Data

Jules Manger, MD

Urology · Tucson, AZNPI 1144464439

Payments from drug & device makers

$4,727in general payments, 2019–2025

Across 188 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$840
  • Astellas Pharma US Inc$590
  • Dendreon Pharmaceuticals LLC$370
  • Bayer$301
  • Myovant Sciences Inc.$277
  • Amgen$247
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$50511%
  • Food & beverage$3,60376%
  • Education$61913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,727 in reported general payments places this provider in the 50th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$486,069
Medicare patients
974
Services billed
19,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix87$225,145
GemtesaVibegron83$61,850
MyrbetriqMirabegron48$38,852
Testosterone25$6,589
Tamsulosin Hcl475$6,066
Finasteride529$5,571
Solifenacin Succinate46$2,831
Potassium Citrate ErPotassium Citrate29$2,358
Tolterodine Tartrate ErTolterodine Tartrate12$1,838
NitrofurantoinNitrofurantoin Macrocrystal38$1,225
Testosterone Cypionate50$1,121
Alfuzosin Hcl ErAlfuzosin Hcl42$753
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen132$660
Ciprofloxacin Hcl87$343
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim101$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$149$286,995170 claims
Astellas Pharma US IncMyrbetriq$590$38,85248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 269 urology providers in Arizona.

Other urology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →